Johannes Czernin - Publications

Affiliations: 
Molec & Med Pharmacology 0639 University of California, Los Angeles, Los Angeles, CA 
Area:
Immunology, Human Development, Biochemistry
Website:
https://www.uclahealth.org/johannes-czernin

284 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Taddio MF, Doshi S, Masri M, Jeanjean P, Hikmat F, Gerlach A, Nyiranshuti L, Rosser EW, Schaue D, Besserer-Offroy E, Carlucci G, Radu CG, Czernin J, Lückerath K, Mona CE. Evaluating [Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. European Journal of Nuclear Medicine and Molecular Imaging. PMID 39008063 DOI: 10.1007/s00259-024-06809-4  0.549
2024 Schelbert H, Schöder H, Czernin J. Illuminating Cardiac Function: Heinz Schelbert Talks with Heiko Schöder and Johannes Czernin About a Pioneering Career in Nuclear Cardiology. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 65: 1163-1165. PMID 38991749 DOI: 10.2967/jnumed.124.268302  0.39
2022 Chen BY, Salas JR, Trias AO, Perez Rodriguez A, Tsang JE, Guemes M, Le TM, Galic Z, Shepard HM, Steinman L, Nathanson DA, Czernin J, Witte ON, Radu CG, Schultz KA, et al. Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis. Immunology. PMID 35986643 DOI: 10.1111/imm.13569  0.503
2022 Beyer T, Czernin J, Freudenberg LS, Giesel F, Hacker M, Hicks RJ, Krause B. A 2022 INTERNATIONAL SURVEY ON THE STATUS OF PROSTATE CANCER THERANOSTICS. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 35953304 DOI: 10.2967/jnumed.122.264298  0.329
2022 Czernin J, Adams T, Calais J. More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 63: 969-970. PMID 35772954 DOI: 10.2967/jnumed.121.264374  0.3
2022 Le TM, Lee HR, Abt ER, Rashid K, Creech AL, Liang K, Cui J, Cho A, Wei L, Labora A, Chan C, Sanchez E, Kriti K, Karin D, Li L, ... ... Czernin J, et al. F-FDG PET visualizes systemic STING agonist-induced lymphocyte activation in preclinical models. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 35738905 DOI: 10.2967/jnumed.122.264121  0.64
2022 Abt ER, Le TM, Dann AM, Capri JR, Poddar S, Lok V, Li L, Liang K, Creech AL, Rashid K, Kim W, Wu N, Cui J, Cho A, Lee HR, ... ... Czernin J, et al. Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Cell Reports. 38: 110236. PMID 35021095 DOI: 10.1016/j.celrep.2021.110236  0.527
2021 Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach MS, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter R, et al. Head-to-head comparison of Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 34649942 DOI: 10.2967/jnumed.121.262398  0.321
2021 Crompton J, Armstrong WR, Eckardt MA, Seyedroudbari A, Tap WD, Dry SM, Abt ER, Calais J, Herrmann K, Czernin J, Eilber FC, Benz MR. F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 34593596 DOI: 10.2967/jnumed.121.262502  0.389
2021 Liang K, Abt ER, Le TM, Cho A, Dann AM, Cui J, Li L, Rashid K, Creech AL, Wei L, Ghukasyan R, Rosser EW, Wu N, Carlucci G, Czernin J, et al. STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [F]FLT PET imaging. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34480004 DOI: 10.1073/pnas.2105390118  0.652
2021 Czernin J, Radu C, Ribas A. Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni Ribas. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 62: 1178-1180. PMID 34475241 DOI: 10.2967/jnumed.121.262937  0.488
2021 Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J. F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 34272317 DOI: 10.2967/jnumed.121.261952  0.372
2021 Czernin J, Iagaru A. Humana and F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 62: 1-2. PMID 33334909  0.325
2020 Sun DL, Poddar S, Pan RD, Rosser EW, Abt ER, Van Valkenburgh J, Le TM, Lok V, Hernandez SP, Song J, Li J, Turlik A, Chen X, Cheng CA, Chen W, ... ... Czernin J, et al. Isoquinoline thiosemicarbazone displays potent anticancer activity with efficacy against aggressive leukemias. Rsc Medicinal Chemistry. 11: 392-410. PMID 33479645 DOI: 10.1039/c9md00594c  0.528
2020 Czernin J, Radu C. The Solutions Come from Science and Knowledge. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 33310739 DOI: 10.2967/jnumed.120.261792  0.434
2020 Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J, Herrmann K, Kostakoglu L, Lewis JS, Mankoff DA, et al. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 61: 263S-272S. PMID 33293447 DOI: 10.2967/jnumed.120.254532  0.45
2020 Stuparu AD, Capri JR, Meyer C, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, et al. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 33277393 DOI: 10.2967/jnumed.120.256263  0.545
2020 Czernin J, Iagaru A. Humana and F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 33188152 DOI: 10.2967/jnumed.120.260208  0.325
2020 Polverari G, Ceci F, Passera R, Crane J, Du L, Li G, Fanti S, Bernthal N, Eilber FC, Allen-Auerbach M, Czernin J, Calais J, Federman N. [F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. Ejnmmi Research. 10: 122. PMID 33063147 DOI: 10.1186/s13550-020-00715-0  0.34
2020 Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. European Urology Oncology. PMID 32958451 DOI: 10.1016/J.Euo.2020.08.012  0.371
2020 Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, Slavik R, Carroll PR, Lawhn-Heath C, ... ... Czernin J, et al. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32808077 DOI: 10.1007/S00259-020-04945-1  0.376
2020 Hayrapetian A, Girgis MD, Yanagawa J, French SW, Schelbert HR, Auerbach MS, Czernin J, Calais J. Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer. Clinical Nuclear Medicine. PMID 32701818 DOI: 10.1097/Rlu.0000000000003218  0.611
2020 Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lueckerath K. Immune-Checkpoint Blockade Enhances Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32646877 DOI: 10.2967/Jnumed.120.246041  0.56
2020 Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH, Reiter RE, Rettig MB, Gartmann J, Murthy V, Slavik R, Carroll PR, et al. Impact of Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32358094 DOI: 10.2967/Jnumed.120.242180  0.356
2020 Stuparu AD, Meyer CAL, Evans-Axelsson SL, Lückerath K, Wei LH, Kim W, Poddar S, Mona CE, Dahlbom M, Girgis MD, Radu CG, Czernin J, Slavik R. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study. Theranostics. 10: 2612-2620. PMID 32194823 DOI: 10.7150/Thno.42228  0.585
2020 Oughourlian TC, Yao J, Schlossman J, Raymond C, Ji M, Tatekawa H, Salamon N, Pope WB, Czernin J, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Rate of change in maximum F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. Journal of Neuro-Oncology. PMID 31981013 DOI: 10.1007/S11060-020-03407-W  0.434
2020 Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intra-tumoral PSMA heterogeneity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31932492 DOI: 10.1158/1078-0432.Ccr-19-1485  0.579
2020 Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter R, Czernin J, Calais J. Impact of Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single Center Study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31924715 DOI: 10.2967/Jnumed.119.237602  0.398
2020 Fendler W, Ferdinandus J, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig M, Gartmann J, Smith R, Small EJ, Slavik R, Carroll P, ... ... Czernin J, et al. Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. Journal of Clinical Oncology. 38: 292-292. DOI: 10.1200/Jco.2020.38.6_Suppl.292  0.371
2020 Sonni I, Eiber M, Fendler W, Alano RM, Vangala SS, Kishan AU, Nickols NG, Rettig M, Reiter RE, Czernin J, Calais J. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings. Journal of Clinical Oncology. 38: 26-26. DOI: 10.1200/Jco.2020.38.6_Suppl.26  0.379
2020 Armstrong WR, Thin P, Nguyen K, Alano RM, Booker KM, Gartmann J, Lok V, Lira S, Czernin J, Kishan AU, Nickols NG, Calais J. Comparison of recurrence patterns after surgery and radiation therapy with 68Ga-PSMA-11 PET/CT in nonmetastatic castrate-sensitive prostate cancer patients: A single-center post-hoc retrospective analysis in 787 patients. Journal of Clinical Oncology. 38: 3577-3577. DOI: 10.1200/Jco.2020.38.15_Suppl.3577  0.326
2019 Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. Radiation dosimetry and biodistribution of Ga-FAPI-46 PET imaging in cancer patients. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31836685 DOI: 10.2967/Jnumed.119.236786  0.396
2019 Gafita A, Calais J, Franz C, Rauscher I, Wang H, Roberstson A, Czernin J, Weber WA, Eiber M. Evaluation of SUV normalized by lean body mass (SUL) in Ga-PSMA11 PET/CT: a bi-centric analysis. Ejnmmi Research. 9: 103. PMID 31792771 DOI: 10.1186/S13550-019-0572-Z  0.369
2019 Abt ER, Rosser EW, Durst MA, Lok V, Poddar S, Le TM, Cho A, Kim W, Wei L, Song J, Capri JR, Xu S, Wu N, Slavik R, Jung ME, ... ... Czernin J, et al. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chemical Biology. PMID 31734178 DOI: 10.1016/J.Chembiol.2019.10.012  0.57
2019 Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J. What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply. The Lancet. Oncology. 20: e609-e610. PMID 31674314 DOI: 10.1016/S1470-2045(19)30654-0  0.364
2019 Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Willliams J, Calais J. Total-body Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: Potential impact on bone scan guidelines. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31541035 DOI: 10.2967/Jnumed.119.230318  0.36
2019 Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, et al. Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31511295 DOI: 10.1158/1078-0432.Ccr-19-1050  0.358
2019 Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, et al. EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging. PMID 31440799 DOI: 10.1007/S00259-019-04485-3  0.303
2019 Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, ... ... Czernin J, et al. F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. The Lancet. Oncology. PMID 31375469 DOI: 10.1016/S1470-2045(19)30415-2  0.434
2019 Rauscher I, Fendler WP, Hope T, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M. Can the injected dose be reduced in Ga-PSMA-11 PET/CT maintaining high image quality for lesion detection? Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31324710 DOI: 10.2967/Jnumed.119.227207  0.323
2019 Zhu S, Mosessian S, Kroeger K, Sadeghi S, Slavik R, Kinloch S, Moore M, Allen-Auerbach M, Czernin J, Phelps M. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31240531 DOI: 10.1007/S11307-019-01395-6  0.329
2019 Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, ... ... Czernin J, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. Jama Oncology. PMID 30920593 DOI: 10.1001/Jamaoncol.2019.0096  0.393
2019 Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NNG. Randomized prospective phase III trial of Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. Bmc Cancer. 19: 18. PMID 30616601 DOI: 10.1200/Jco.2019.37.15_Suppl.Tps5101  0.413
2019 Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps136  0.34
2019 Calais J, Ceci F, Nguyen K, Gartmann J, Eiber M, Reiter RE, Kishan AU, Jadvar H, Fendler WP, Czernin J. Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy. Journal of Clinical Oncology. 37: 15-15. DOI: 10.1200/Jco.2019.37.7_Suppl.15  0.427
2019 Calais J, Fendler WP, Eiber M, Lassmann M, Dahlbom M, Esfandiari R, Gartmann J, Nguyen K, Thin P, Lok V, Herrmann K, Czernin J, Delpassand E. RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology. 37: 5028-5028. DOI: 10.1200/Jco.2019.37.15_Suppl.5028  0.318
2019 Calais J, Ceci F, Eiber M, Bach-Gansmo T, Nanni C, Savir-Baruch B, Hofman M, Hope T, Rischpler C, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Reiter RE, ... ... Czernin J, et al. Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer. Journal of Clinical Oncology. 37: 5014-5014. DOI: 10.1200/Jco.2019.37.15_Suppl.5014  0.439
2019 Calais J, Ceci F, Eiber M, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Reiter R, Rettig M, Jadvar H, Bach-Gansmo T, Savir-Barush B, ... ... Czernin J, et al. Lba-21 68Ga-Psma-11 Pet/Ct Detects Prostate Cancer At Early Biochemical Recurrence With Superior Detection Rate And Reader Agreement When Compared To 18F-Fluciclovine Pet/Ct In A Prospective Head-To-Head Comparative Phase 3 Study The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557513.53829.A8  0.428
2019 Pooli A, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Calais J, Reiter RE. PD40-11 THE ROLE OF 68GA-PSMA PET-CT IN INITIAL STAGING OF TREATMENT-NAïVE HIGH RISK PROSTATE CANCER. The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556543.86104.2A  0.381
2019 Yao J, Nathanson D, Yong WH, Salamon N, Lai A, Leia Nghiemphu P, Prins R, Pope W, Czernin J, Everson R, Liau L, Cloughesy T, Ellingson B. NIMG-60. IDH MUTANT GLIOMAS WITH 1p/19q CO-DELETION ARE LESS ACIDIC THAN NON-CO-DELETED GLIOMAS AS MEASURED WITH PH-WEIGHTED AMINE CEST-MRI AND AMINO ACID PET Neuro-Oncology. 21: vi174-vi175. DOI: 10.1093/Neuonc/Noz175.729  0.305
2019 Fendler W, Weber M, Iravani A, Hofman M, Calais J, Czernin J, Ilhan H, Maurer T, Herrmann K, Hope T, Rauscher I, Hadaschik B, Eiber M. PSMA-PET localizes M1 Disease in more than half of "non-metastatic" Castration-Resistant Prostate Cancer Patients The Journal of Nuclear Medicine. 60: 591-591. DOI: 10.1055/S-0039-1683571  0.333
2019 Hadaschik B, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, et al. Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30510-X  0.4
2019 Meyer C, Stuparu A, Wei L, Capri J, Le T, Radu C, Czernin J, Dahlbom M, Slavik R. Therapeutic Efficacy and Dosimetry of Targeted Alpha Therapy using 225Ac-PSMA-617 in a Murine Model of Prostate Cancer Journal of Medical Imaging and Radiation Sciences. 50: S24. DOI: 10.1016/J.Jmir.2019.03.075  0.557
2018 Maddahi J, Bengel F, Czernin J, Crane P, Dahlbom M, Schelbert H, Sparks R, Phelps M, Lazewatsky J. Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging. Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology. PMID 30488323 DOI: 10.1007/S12350-018-01484-Z  0.587
2018 Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. Ejnmmi Research. 8: 96. PMID 30374743 DOI: 10.1186/S13550-018-0451-Z  0.574
2018 Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by Ga-PSMA-11 PET/CT. Clinical Genitourinary Cancer. PMID 30293922 DOI: 10.1016/J.Clgc.2018.09.003  0.352
2018 Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. Journal of Neuro-Oncology. PMID 29679199 DOI: 10.1007/S11060-018-2877-6  0.429
2018 Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Matthew RB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. Potential impact of Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29653978 DOI: 10.2967/Jnumed.118.209387  0.394
2018 Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler W. Detection threshold and reproducibility ofGa-PSMA11 PET/CT in a mouse model of prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29602819 DOI: 10.2967/Jnumed.118.207704  0.654
2018 Czernin J. The National Oncologic PET Registry (NOPR): A Monumental Effort by a Few Leaders. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 59: 379. PMID 29497001 DOI: 10.2967/jnumed.117.207860  0.319
2018 Czernin J. The National Oncology PET Registry (NOPR): A monumental effort by a few leaders. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29371409 DOI: 10.2967/Jnumed.118.207860  0.432
2018 Fendler W, Calais J, Gartmann J, Nickols NG, Reiter RE, Rettig M, Hope TA, Slavik R, Gupta P, Quon A, Allen-Auerbach M, Herrmann K, Czernin J, Eiber M. Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial. Journal of Clinical Oncology. 36: 5001-5001. DOI: 10.1200/Jco.2018.36.15_Suppl.5001  0.377
2018 Elkhoury F, Calais J, Czernin J, Fendler W, Herrmann K, Eiber M, Ceci F, Reiter R, Marks L. Mp20-16 68Ga-Psma-11 Pet/Ct Vs 18F-Fluciclovine Pet/Ct: A Case Series In Prostate Cancer Patients With Biochemical Recurrence The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.686  0.438
2017 Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RR, Rettig MB, Marks LS, Ahlering TE, Huynh L, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, ... Czernin J, et al. Actual impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29242398 DOI: 10.2967/Jnumed.117.202945  0.36
2017 Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler KA, Chu FI, King CR, Steinberg ML, Rausher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, et al. (68)Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29123013 DOI: 10.2967/Jnumed.117.201749  0.361
2017 Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings of the National Academy of Sciences of the United States of America. PMID 28874539 DOI: 10.1073/Pnas.1706689114  0.74
2017 Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, ... ... Czernin J, et al. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nature Communications. 8: 241. PMID 28808226 DOI: 10.1038/S41467-017-00221-3  0.584
2017 Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K. Establishing (177)Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28546332 DOI: 10.2967/Jnumed.117.193359  0.561
2017 Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney A, Hendifar A, Pisegna J, Hecht JR, Wolin E, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach M, et al. Most intended management changes after (68)Ga-DOTATATE PET/CT are implemented. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28473600 DOI: 10.2967/Jnumed.117.192450  0.37
2017 Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, ... ... Czernin J, et al. (68)Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28408531 DOI: 10.2967/Jnumed.117.190827  0.372
2017 Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Science Translational Medicine. 9. PMID 28100832 DOI: 10.1126/Scitranslmed.Aag2196  0.434
2017 Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, et al. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Reports. 18: 601-610. PMID 28099841 DOI: 10.1016/J.Celrep.2016.12.061  0.597
2017 Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, Eiber M, Herrmann K, Fendler WP. The impact of SSTR-directed PET/CT on the management of patients with neuroendocrine tumor: A systematic review and meta-analysis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28082438 DOI: 10.2967/Jnumed.116.185587  0.415
2017 Soto H, Antonios J, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI Neuro-Oncology. 19: vi149-vi150. DOI: 10.1093/Neuonc/Nox168.611  0.612
2016 Barrio M, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach MS, Schiepers C, Slavik R, Czernin J, Herrmann K. Human biodistribution and radiation dosimetry of 18F-CFA, a PET probe targeting the deoxyribonucleoside salvage pathway. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27811125 DOI: 10.2967/Jnumed.116.182394  0.65
2016 Forgacs A, Pall Jonsson H, Dahlbom M, Daver F, D DiFranco M, Opposits G, K Krizsan A, Garai I, Czernin J, Varga J, Tron L, Balkay L. A Study on the Basic Criteria for Selecting Heterogeneity Parameters of F18-FDG PET Images. Plos One. 11: e0164113. PMID 27736888 DOI: 10.1371/Journal.Pone.0164113  0.443
2016 Spick C, Herrmann K, Czernin J. Evaluation of Prostate Cancer with 11C-Acetate PET/CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 30S-37S. PMID 27694168 DOI: 10.2967/Jnumed.115.169599  0.354
2016 Barrio M, Fendler WP, Czernin J, Herrmann K. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Review of Molecular Diagnostics. PMID 27679869 DOI: 10.1080/14737159.2016.1243057  0.322
2016 Barrio M, Czernin J, Yeh MW, Palma Diaz MF, Gupta P, Allen-Auerbach M, Schiepers C, Herrmann K. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients. Nuclear Medicine Communications. PMID 27612034 DOI: 10.1097/Mnm.0000000000000592  0.453
2016 Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, Bluemel C, Grewal R, Lapa C, Miederer M, Nicolas G, Schuster T, Czernin J, Herrmann K. 68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessments: results from a prospective study on 50 patients. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27539839 DOI: 10.2967/Jnumed.116.179192  0.398
2016 Fendler WP, Czernin J, Herrmann K, Beyer T. Variations in PET/MRI operations: Results from an international survey among 39 active sites. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27516448 DOI: 10.2967/Jnumed.116.174169  0.39
2016 Boschi S, Lee JT, Beykan S, Slavik R, Wei L, Spick C, Eberlein U, Buck AK, Lodi F, Cicoria G, Czernin J, Lassmann M, Fanti S, Herrmann K. Synthesis and preclinical evaluation of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. European Journal of Nuclear Medicine and Molecular Imaging. PMID 27329046 DOI: 10.1007/S00259-016-3437-Y  0.599
2016 Langsteger W, Rezaee A, Loidl W, Geinitz HS, Fitz F, Steinmair M, Broinger G, Pallwien-Prettner L, Beheshti M, Imamovic L, Beheshti M, Rendl G, Hackl D, Tsybrovsky O, Steinmair M, ... ... Czernin J, et al. 32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016. Ejnmmi Research. 6: 32. PMID 27090254 DOI: 10.1186/S13550-016-0168-9  0.387
2016 Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, ... ... Czernin J, et al. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proceedings of the National Academy of Sciences of the United States of America. PMID 27035974 DOI: 10.1073/Pnas.1524212113  0.821
2016 Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, et al. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clinical Nuclear Medicine. PMID 26975008 DOI: 10.1097/Rlu.0000000000001197  0.441
2016 Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 420-30. PMID 26742709 DOI: 10.2967/Jnumed.115.158808  0.477
2016 Fendler WP, Bluemel C, Czernin J, Herrmann K. PET imaging in prostate cancer, future trends: PSMA ligands Clinical and Translational Imaging. 4: 467-472. DOI: 10.1007/S40336-016-0194-7  0.393
2015 Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Bremerich J, Czernin J, Drzezga A, Franzius C, Goh V, Hartenbach M, Iida H, Kjaer A, la Fougère C, Ladefoged CN, et al. Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here : Summary Report of the 4th International Workshop on PET/MR Imaging; February 23-27, 2015, Tübingen, Germany. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 17: 595-608. PMID 26286794 DOI: 10.1007/S11307-015-0886-9  0.431
2015 Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 855-61. PMID 25883128 DOI: 10.2967/Jnumed.115.156133  0.331
2015 Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 70-5. PMID 25500825 DOI: 10.2967/Jnumed.114.148247  0.377
2015 Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 17: 434-42. PMID 25465392 DOI: 10.1007/S11307-014-0807-3  0.426
2015 Patel C, Nguyen H, Manoukian J, Ellingson B, Czernin J, Cloughesy T, Nghiemphu P, Lai A. NIMG-57QUANTITATION OF 18F-DOPA UPTAKE ON PET PREDICTS TUMOR GRADE WITH HIGH SENSITIVITY AND SPECIFICITY IN NEWLY-DIAGNOSED GLIOMA: UCLA EXPERIENCE Neuro-Oncology. 17: v167.1-v167. DOI: 10.1093/Neuonc/Nov225.57  0.372
2014 Karantanis D, Kalkanis D, Czernin J, Herrmann K, Pomykala KL, Bogsrud TV, Subramaniam RM, Lowe VJ, Allen-Auerbach MS. Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 1925-9. PMID 25453041 DOI: 10.2967/Jnumed.114.145607  0.463
2014 Nomme J, Li Z, Gipson RM, Wang J, Armijo AL, Le T, Poddar S, Smith T, Santarsiero BD, Nguyen HA, Czernin J, Alexandrova AN, Jung ME, Radu CG, Lavie A. Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability. Journal of Medicinal Chemistry. 57: 9480-94. PMID 25341194 DOI: 10.1021/Jm501124J  0.566
2014 Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Löhr M, Herrmann K. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 1611-6. PMID 25125481 DOI: 10.2967/Jnumed.114.140608  0.417
2014 Packard RR, Huang SC, Dahlbom M, Czernin J, Maddahi J. Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 1438-44. PMID 25071096 DOI: 10.2967/Jnumed.114.141093  0.41
2014 Czernin J, Ta L, Herrmann K. Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 59S-62S. PMID 24812246 DOI: 10.2967/Jnumed.114.141838  0.406
2014 Lajtos I, Czernin J, Dahlbom M, Daver F, Emri M, Farshchi-Heydari S, Forgacs A, Hoh CK, Joszai I, Krizsan AK, Lantos J, Major P, Molnar J, Opposits G, Tron L, et al. Cold wall effect eliminating method to determine the contrast recovery coefficient for small animal PET scanners using the NEMA NU-4 image quality phantom. Physics in Medicine and Biology. 59: 2727-46. PMID 24800813 DOI: 10.1088/0031-9155/59/11/2727  0.346
2014 Mosessian S, Duarte-Vogel SM, Stout DB, Roos KP, Lawson GW, Jordan MC, Ogden A, Matter C, Sadeghi S, Mills GQ, Schelbert HR, Radu CG, Czernin J, Couto M, Phelps ME. INDs for PET molecular imaging probes-approach by an academic institution. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 16: 441-8. PMID 24733693 DOI: 10.1007/S11307-014-0735-2  0.735
2014 Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3550-9. PMID 24687922 DOI: 10.1158/1078-0432.Ccr-13-1440  0.459
2014 Bailey DL, Barthel H, Beuthin-Baumann B, Beyer T, Bisdas S, Boellaard R, Czernin J, Drzezga A, Ernemann U, Franzius C, Gückel B, Handgretinger R, Hartenbach M, Hellwig D, Nadel H, et al. Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 16: 295-310. PMID 24668195 DOI: 10.1007/S11307-014-0725-4  0.444
2014 Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2457-65. PMID 24634374 DOI: 10.1158/1078-0432.Ccr-13-3017  0.551
2014 Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, ... ... Czernin J, et al. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. The Journal of Experimental Medicine. 211: 473-86. PMID 24567448 DOI: 10.1084/Jem.20131738  0.796
2014 Javed MR, Chen S, Kim HK, Wei L, Czernin J, Kim CJ, van Dam RM, Keng PY. Efficient radiosynthesis of 3'-deoxy-3'-18F-fluorothymidine using electrowetting-on-dielectric digital microfluidic chip. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 321-8. PMID 24365651 DOI: 10.2967/Jnumed.113.121053  0.411
2014 Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro-Oncology. 16: 603-9. PMID 24305722 DOI: 10.1093/Neuonc/Not166  0.405
2014 Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, Chen W. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 30-6. PMID 24167081 DOI: 10.2967/Jnumed.113.121418  0.37
2014 Radu CG, Nathanson DA, Czernin J. Abstract 5097: Co-targeting of convergent, switchable nucleotide biosynthetic pathways induces synthetic lethality in leukemia Cancer Research. 74: 5097-5097. DOI: 10.1158/1538-7445.Am2014-5097  0.607
2014 Schwarzenberg J, Czernin J, Cloughesy T, Lai A, Phelps M, Chen W. NI-68 * 18F-FDOPA PET IN TREATED LOW-GRADE GLIOMAS WITH NON-ENHANCING T2 CHANGES ON MRI IS PROGNOSTIC OF TUMOR PROGRESSION AND OVERALL SURVIVAL Neuro-Oncology. 16: v153-v153. DOI: 10.1093/Neuonc/Nou264.66  0.446
2013 Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. Pet Clinics. 8: 201-17. PMID 27157948 DOI: 10.1016/J.Cpet.2012.09.002  0.432
2013 Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K. PET/CT in Oncology: Current Status and Perspectives. Current Radiology Reports. 1: 177-190. PMID 24883234 DOI: 10.1007/S40134-013-0016-X  0.46
2013 Allen-Auerbach M, de Vos S, Czernin J. PET/computed tomography and lymphoma. Radiologic Clinics of North America. 51: 833-44. PMID 24010908 DOI: 10.1016/J.Rcl.2013.05.004  0.449
2013 Murphy JM, Armijo AL, Nomme J, Lee CH, Smith QA, Li Z, Campbell DO, Liao HI, Nathanson DA, Austin WR, Lee JT, Darvish R, Wei L, Wang J, Su Y, ... ... Czernin J, et al. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography. Journal of Medicinal Chemistry. 56: 6696-708. PMID 23947754 DOI: 10.1021/Jm400457Y  0.81
2013 Amaraesekera B, Marchis PD, Bobinski KP, Radu CG, Czernin J, Barrio JR, Michael van Dam R. High-pressure, compact, modular radiosynthesizer for production of positron emitting biomarkers. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 78: 88-101. PMID 23702794 DOI: 10.1016/J.Apradiso.2013.04.024  0.575
2013 Czernin J, Herrmann K. The potential of PET/MRI imaging in oncology: a comment to a summary report of the First PET/MRI Workshop in Tuebingen in 2012. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 15: 372-3. PMID 23689984 DOI: 10.1007/S11307-013-0642-Y  0.468
2013 Herrmann K, Dahlbom M, Nathanson D, Wei L, Radu C, Chatziioannou A, Czernin J. Evaluation of the Genisys4, a bench-top preclinical PET scanner. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 1162-7. PMID 23628700 DOI: 10.2967/Jnumed.112.114926  0.668
2013 Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, Shaw RJ. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 23: 143-58. PMID 23352126 DOI: 10.1016/J.Ccr.2012.12.008  0.326
2013 Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. Journal of the American College of Cardiology. 61: 469-77. PMID 23265345 DOI: 10.1016/J.Jacc.2012.11.022  0.385
2013 Mocharla VP, Walsh JC, Padgett HC, Su H, Fueger B, Weber WA, Czernin J, Kolb HC. From in situ to in vivo: an in situ click-chemistry-derived carbonic anhydrase II imaging agent for positron emission tomography. Chemmedchem. 8: 43-8. PMID 23208787 DOI: 10.1002/Cmdc.201200466  0.466
2013 Mocharla VP, Walsh JC, Padgett HC, Su H, Fueger B, Weber WA, Czernin J, Kolb HC. Inside Cover: From In Situ to In Vivo: An In Situ Click‐Chemistry‐Derived Carbonic Anhydrase II Imaging Agent for Positron Emission Tomography (ChemMedChem 1/2013) Chemmedchem. 8: 2-2. DOI: 10.1002/Cmdc.201290066  0.333
2012 Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, Herschman HR, Phelps ME, Witte ON, Czernin J, Radu CG. Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. The Journal of Experimental Medicine. 209: 2215-28. PMID 23148236 DOI: 10.1084/Jem.20121061  0.765
2012 Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud TV, Subramaniam RM, Danielson A, Lowe VJ, Czernin J. Oncologic 18F-FDG PET/CT: referring physicians' point of view. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1499-505. PMID 22917886 DOI: 10.2967/Jnumed.111.102228  0.438
2012 Lee P, Kupelian P, Czernin J, Ghosh P. Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer. Frontiers in Oncology. 2: 71. PMID 22798989 DOI: 10.3389/Fonc.2012.00071  0.455
2012 Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro-Oncology. 14: 1079-89. PMID 22711609 DOI: 10.1093/Neuonc/Nos141  0.47
2012 Beyer T, Freundenberg LS, Czernin J, Townsend DW. Erratum to: The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Into Imaging. 3: 189. PMID 22696045 DOI: 10.1007/S13244-011-0136-X  0.326
2012 Yaghoubi SS, Campbell DO, Radu CG, Czernin J. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. Theranostics. 2: 374-91. PMID 22509201 DOI: 10.7150/Thno.3677  0.651
2012 Karantanis D, Allen-Auerbach M, Czernin J. Squamous papilloma of the oral cavity and oropharynx on 18F-FDG PET/CT imaging. Clinical Nuclear Medicine. 37: e98-9. PMID 22475925 DOI: 10.1097/Rlu.0B013E318238F52D  0.452
2012 Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2024-31. PMID 22338012 DOI: 10.1158/1078-0432.Ccr-11-2139  0.455
2012 Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 393-8. PMID 22323780 DOI: 10.2967/Jnumed.111.095711  0.438
2012 Lee JT, Campbell DO, Satyamurthy N, Czernin J, Radu CG. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 275-80. PMID 22302964 DOI: 10.2967/Jnumed.111.090407  0.721
2012 Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 29-36. PMID 22159180 DOI: 10.2967/Jnumed.111.092387  0.448
2012 Karantanis D, Allen-Auerbach M, Czernin J. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clinical Nuclear Medicine. 37: 49-53. PMID 22157028 DOI: 10.1097/Rlu.0B013E3182291E03  0.451
2012 Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients? Journal of Pediatric Hematology/Oncology. 34: 131-6. PMID 22134608 DOI: 10.1097/Mph.0B013E3182282825  0.47
2012 Campbell DO, Yaghoubi SS, Su Y, Lee JT, Auerbach MS, Herschman H, Satyamurthy N, Czernin J, Lavie A, Radu CG. Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe. The Journal of Biological Chemistry. 287: 446-54. PMID 22074768 DOI: 10.1074/Jbc.M111.314666  0.726
2012 Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer. 118: 3135-44. PMID 22020872 DOI: 10.1002/Cncr.26630  0.673
2012 Herrmann K, Benz MR, Czernin J, Auerbach M, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Eilber FC. 18f-FDG-PET imaging as an early survival predictor in patients with high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Journal of Clinical Oncology. 30: 10012-10012. DOI: 10.1200/Jco.2012.30.15_Suppl.10012  0.447
2012 Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Response to Larry R. White's letter to the editor titled "comparison of CT, PET, and PET/CT for staging of patientswith indolent non-hodgkin's lymphoma: Statistical errors in Fueger et al. (2009)" Molecular Imaging and Biology. 14: 399-401. DOI: 10.1007/S11307-012-0565-Z  0.36
2011 Beyer T, Townsend DW, Czernin J, Freudenberg LS. The future of hybrid imaging-part 2: PET/CT. Insights Into Imaging. 2: 225-34. PMID 23099865 DOI: 10.1007/S13244-011-0069-4  0.413
2011 Beyer T, Freudenberg LS, Townsend DW, Czernin J. The future of hybrid imaging-part 1: hybrid imaging technologies and SPECT/CT. Insights Into Imaging. 2: 161-9. PMID 23099842 DOI: 10.1007/S13244-010-0063-2  0.352
2011 Beyer T, Freudenberg LS, Czernin J, Townsend DW. The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Into Imaging. 2: 235-246. PMID 22347950 DOI: 10.1007/S13244-011-0085-4  0.405
2011 Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czernin J. (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [and] the International Association of Radiopharmacology (Iar), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology. 55: 620-32. PMID 22231582  0.381
2011 Yang Y, Czernin J. Contribution of imaging to cancer care costs. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 86S-92S. PMID 22144560 DOI: 10.2967/Jnumed.110.085621  0.359
2011 Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 1684-9. PMID 22045706 DOI: 10.2967/Jnumed.111.095257  0.425
2011 Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients. Pediatric Hematology and Oncology. 28: 579-87. PMID 21936620 DOI: 10.3109/08880018.2011.602180  0.463
2011 Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6553-62. PMID 21868765 DOI: 10.1158/1078-0432.Ccr-10-3290  0.422
2011 Maddahi J, Czernin J, Lazewatsky J, Huang SC, Dahlbom M, Schelbert H, Sparks R, Ehlgen A, Crane P, Zhu Q, Devine M, Phelps M. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 1490-8. PMID 21849402 DOI: 10.2967/Jnumed.111.092528  0.601
2011 Ng QK, Su H, Armijo AL, Czernin J, Radu CG, Segura T. Clustered Arg-Gly-Asp peptides enhances tumor targeting of nonviral vectors. Chemmedchem. 6: 623-7. PMID 21442757 DOI: 10.1002/Cmdc.201000541  0.569
2011 Czernin J, Benz MR, Allen-Auerbach MS. Breast cancer. Methods in Molecular Biology (Clifton, N.J.). 727: 141-70. PMID 21331933 DOI: 10.1007/978-1-61779-062-1_9  0.36
2011 Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 303-10. PMID 21233186 DOI: 10.2967/Jnumed.110.079624  0.397
2011 Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, Bockisch A, Phelps ME, Czernin J, Weber WA. Metabolic imaging allows early prediction of response to vandetanib. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 231-40. PMID 21233183 DOI: 10.2967/Jnumed.110.081745  0.765
2011 Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. European Journal of Nuclear Medicine and Molecular Imaging. 38: 711-21. PMID 21127859 DOI: 10.1007/S00259-010-1666-Z  0.68
2011 Macapinlac HA, Czernin J, Larson SM. Practice based evidence of the beneficial impact of PET in patients with brain tumors. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 13: 1-2. PMID 21082268 DOI: 10.1007/S11307-010-0446-2  0.474
2011 Ribas A, Chodon T, Comin-Anduix B, Sondergaard J, Mok S, Ng C, Escuin-Ordinas H, Atefi M, Chmielowski B, Czernin J, Witte ON, Radu CG, Koya RC. Abstract SY03-04: Novel imaging approaches for immunotherapy and targeted therapy of melanoma in animal models and humans Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Sy03-04  0.694
2011 Radu C, Lee JT, Campbell DO, Czernin J. Abstract SY03-02: Tumor metabolic phenotyping and treatment stratification by positron emission tomography Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Sy03-02  0.676
2010 Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1826-9. PMID 21078790 DOI: 10.2967/Jnumed.110.077933  0.392
2010 Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1532-8. PMID 20847166 DOI: 10.2967/Jnumed.110.078592  0.406
2010 Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1174-81. PMID 20660389 DOI: 10.2967/Jnumed.109.074229  0.468
2010 Walter MA, Hildebrandt IJ, Hacke K, Kesner AL, Kelly O, Lawson GW, Phelps ME, Czernin J, Weber WA, Schiestl RH. Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1285-92. PMID 20660381 DOI: 10.2967/Jnumed.109.073585  0.787
2010 Shu CJ, Campbell DO, Lee JT, Tran AQ, Wengrod JC, Witte ON, Phelps ME, Satyamurthy N, Czernin J, Radu CG. Novel PET probes specific for deoxycytidine kinase. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1092-8. PMID 20554721 DOI: 10.2967/Jnumed.109.073361  0.717
2010 Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, Dry SM, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. Sarcoma. 2010: 143540. PMID 20414348 DOI: 10.1155/2010/143540  0.438
2010 Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 720-7. PMID 20395318 DOI: 10.2967/Jnumed.109.068361  0.384
2010 Beyer T, Czernin J. Is conflict of interest in our best interest? European Journal of Nuclear Medicine and Molecular Imaging. 37: 1063-8. PMID 20352208 DOI: 10.1007/S00259-010-1429-X  0.311
2010 Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 340-6. PMID 20150263 DOI: 10.2967/Jnumed.109.070946  0.636
2010 Czernin J, Benz MR, Allen-Auerbach MS. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. European Journal of Radiology. 73: 470-80. PMID 20097498 DOI: 10.1016/J.Ejrad.2009.12.023  0.452
2010 Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, Ishikawa TO, Lehmann LW, Satyamurthy N, Phelps ME, Herschman HR, Czernin J, Witte ON, Radu CG. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proceedings of the National Academy of Sciences of the United States of America. 107: 5551-6. PMID 20080663 DOI: 10.1073/Pnas.0913900107  0.773
2010 Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 116: 451-8. PMID 19924789 DOI: 10.1002/Cncr.24755  0.432
2010 Maddahi J, Czernin J, Ehlgen A, Lazewatsky J, Zhu Q, Phelps M. COMPARISON OF F-18 LABELED BMS747158 PET AND TC-99M LABELED SPECT MYOCARDIAL PERFUSION IMAGING FOR DETECTION AND EVALUATION OF CORONARY ARTERY DISEASE Journal of the American College of Cardiology. 55: A65.E616. DOI: 10.1016/S0735-1097(10)60617-1  0.374
2009 Czernin J, Benz MR, Allen-Auerbach MS. PET Imaging of Prostate Cancer Using C-Acetate. Pet Clinics. 4: 163-172. PMID 21984877 DOI: 10.1016/J.Cpet.2009.05.001  0.438
2009 Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proceedings of the National Academy of Sciences of the United States of America. 106: 12932-7. PMID 19625624 DOI: 10.1073/Pnas.0906606106  0.777
2009 Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CH, Alabi CA, Mack BC, Davis ME. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proceedings of the National Academy of Sciences of the United States of America. 106: 11394-9. PMID 19564622 DOI: 10.1073/Pnas.0905487106  0.767
2009 Wang H, Wang S, Su H, Chen KJ, Armijo AL, Lin WY, Wang Y, Sun J, Kamei K, Czernin J, Radu CG, Tseng HR. A supramolecular approach for preparation of size-controlled nanoparticles. Angewandte Chemie (International Ed. in English). 48: 4344-8. PMID 19425037 DOI: 10.1002/anie.200900063  0.524
2009 Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma. Current Opinion in Oncology. 21: 345-51. PMID 19412096 DOI: 10.1097/Cco.0B013E32832C95E2  0.445
2009 Johnson M, Karanikolas BD, Priceman SJ, Powell R, Black ME, Wu HM, Czernin J, Huang SC, Wu L. Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 757-64. PMID 19372484 DOI: 10.2967/Jnumed.108.058438  0.468
2009 Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2856-63. PMID 19351756 DOI: 10.1158/1078-0432.Ccr-08-2537  0.461
2009 Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 11: 269-74. PMID 19326177 DOI: 10.1007/S11307-009-0200-9  0.408
2009 Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Research. 69: 3173-9. PMID 19318569 DOI: 10.1158/0008-5472.Can-08-3390  0.786
2009 Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 513-9. PMID 19289420 DOI: 10.2967/jnumed.108.058396  0.353
2009 Laing RE, Walter MA, Campbell DO, Herschman HR, Satyamurthy N, Phelps ME, Czernin J, Witte ON, Radu CG. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proceedings of the National Academy of Sciences of the United States of America. 106: 2847-52. PMID 19196993 DOI: 10.1073/Pnas.0812890106  0.68
2009 Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, Gambhir SS. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nature Clinical Practice. Oncology. 6: 53-8. PMID 19015650 DOI: 10.1038/Ncponc1278  0.447
2009 Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. European Journal of Radiology. 71: 242-8. PMID 18511228 DOI: 10.1016/J.Ejrad.2008.04.018  0.468
2009 Kesner AL, Bundschuh RA, Detorie NC, Dahlbom M, Ziegler SI, Czernin J, Silverman DH. Respiratory gated PET derived in a fully automated manner from raw PET data Ieee Transactions On Nuclear Science. 56: 677-686. DOI: 10.1109/Tns.2009.2016341  0.776
2009 Farrell JJ, Tomlinson JS, Czernin J, Radu CG. S1284 Novel Molecular Immune System Imaging of Autoimmune Pancreatitis with L-FAC-PET Imaging: Comparison with FDG-PET Gastroenterology. 136: A-229. DOI: 10.1016/S0016-5085(09)61033-7  0.585
2009 Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, Gambhir SS. Noninvasive detection of therapeutic cytolytic T cells with 18 F-FHBG PET in a patient with glioma Nature Reviews Clinical Oncology. 6: 53-58.  0.339
2008 Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1828-35. PMID 18927335 DOI: 10.2967/Jnumed.108.054452  0.783
2008 Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, Czernin J, Weber WA. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1579-84. PMID 18794268 DOI: 10.2967/Jnumed.108.053694  0.417
2008 Kesner AL, Lau VK, Speiser M, Hsueh WA, Agazaryan N, DeMarco JJ, Czernin J, Silverman DH. Time-course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow. Journal of Applied Clinical Medical Physics / American College of Medical Physics. 9: 2747. PMID 18716585 DOI: 10.1120/Jacmp.V9I3.2747  0.769
2008 Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DH. Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 10: 341-8. PMID 18679756 DOI: 10.1007/S11307-008-0160-5  0.778
2008 Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiologic Clinics of North America. 46: 199-211, vii. PMID 18619376 DOI: 10.1016/J.Rcl.2008.03.004  0.444
2008 Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, Weber WA. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1038-46. PMID 18552153 DOI: 10.2967/Jnumed.107.050187  0.472
2008 Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3416-26. PMID 18519772 DOI: 10.1158/1078-0432.Ccr-07-1824  0.794
2008 Weber WA, Grosu AL, Czernin J. Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning. Nature Clinical Practice. Oncology. 5: 160-70. PMID 18253106 DOI: 10.1038/Ncponc1041  0.426
2008 Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 715-20. PMID 18245531 DOI: 10.1158/1078-0432.Ccr-07-1762  0.417
2008 Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. European Journal of Nuclear Medicine and Molecular Imaging. 35: 1089-99. PMID 18239919 DOI: 10.1007/S00259-007-0636-6  0.372
2008 Weber WA, Czernin J, Phelps ME, Herschman HR. Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nature Clinical Practice. Oncology. 5: 44-54. PMID 18097456 DOI: 10.1038/Ncponc0982  0.33
2008 Benz MR, Weber WA, Allen-Auerbach MS, Tap WD, Elashoff D, Eckardt JJ, Dry SM, Phelps ME, Czernin J, Eilber FC. Tumor FDG-uptake after the initial cycle of chemotherapy and histopathologic response to neoadjuvant therapy in high-grade soft tissue sarcomas Journal of Clinical Oncology. 26: 10528-10528. DOI: 10.1200/Jco.2008.26.15_Suppl.10528  0.322
2007 Kesner AL, Hsueh WA, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DH. Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 2021-7. PMID 18006620 DOI: 10.2967/Jnumed.107.045716  0.764
2007 Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4714-21. PMID 17947718 DOI: 10.1200/Jco.2006.10.5825  0.452
2007 Weber WA, Czernin J, Phelps ME. Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3105-6. PMID 17545510 DOI: 10.1158/1078-0432.Ccr-07-0188  0.421
2007 Lin TW, de Aburto MA, Dahlbom M, Huang LL, Marvi MM, Tang M, Czernin J, Phelps ME, Silverman DH. Predicting seizure-free status for temporal lobe epilepsy patients undergoing surgery: prognostic value of quantifying maximal metabolic asymmetry extending over a specified proportion of the temporal lobe. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 776-82. PMID 17475967 DOI: 10.2967/Jnumed.106.034249  0.304
2007 Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C. Accuracy of PET/CT in characterization of solitary pulmonary lesions. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 214-20. PMID 17268017  0.319
2007 Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. European Journal of Radiology. 62: 199-204. PMID 17223003 DOI: 10.1016/J.Ejrad.2006.11.037  0.451
2007 Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 78S-88S. PMID 17204723  0.579
2007 Czernin J, Schelbert HR. PET/CT in cancer patient management. Introduction. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 2S-3S. PMID 17204715  0.541
2007 Evilevitch V, Weber WA, Tap WD, Chow K, Allen-Auerbach M, Nelson SD, Eilber FR, Eckardt JJ, Czernin J, Eilber FC. Change in quantitative FDG-PET was significantly more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high grade soft tissue sarcomas Journal of Clinical Oncology. 25: 10017-10017. DOI: 10.1200/Jco.2007.25.18_Suppl.10017  0.46
2007 Kesner AL, Dahlbom M, Czernin J, Silverman DHS. Recombining respiratory gated PET frames Ieee Nuclear Science Symposium Conference Record. 5: 3961-3963. DOI: 10.1109/NSSMIC.2007.4436984  0.732
2007 Kesner AL, Bundschuh RA, Detorie NC, Dahlbom M, Czernin J, Silverman DHS. Respiratory gated PET derived from raw PET data Ieee Nuclear Science Symposium Conference Record. 4: 2686-2691. DOI: 10.1109/NSSMIC.2007.4436699  0.765
2006 Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J, Phelps ME, Silverman DH. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 1995-9. PMID 17138742  0.774
2006 Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5659-67. PMID 17020967 DOI: 10.1158/1078-0432.Ccr-06-0368  0.319
2006 Kesner AL, Dahlbom M, Huang SC, Hsueh WA, Pio BS, Czernin J, Kreissl M, Wu HM, Silverman DH. Semiautomated analysis of small-animal PET data. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 1181-6. PMID 16818953  0.769
2006 Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA. Impact of animal handling on the results of 18F-FDG PET studies in mice. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 999-1006. PMID 16741310  0.809
2006 Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 904-11. PMID 16741298  0.37
2006 Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 129: 393-401. PMID 16478857 DOI: 10.1378/Chest.129.2.393  0.512
2006 Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annual Review of Medicine. 57: 99-118. PMID 16409139 DOI: 10.1146/Annurev.Med.57.080904.190431  0.344
2006 Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 8: 36-42. PMID 16362149 DOI: 10.1007/S11307-005-0029-9  0.48
2006 Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Medicine. 12: 122-7. PMID 16341243 DOI: 10.1038/Nm1337  0.442
2006 Dumont RA, Su H, Bodenstein C, Czernin J, Weber W. 57 Quantitative Assessment Of Tumor Glucose Utilization For Prediction Of Response To Treatment With The Epidermal Growth Factor Receptor Kinase Inhibitor Gefitinib (Iressa). Journal of Investigative Medicine. 54. DOI: 10.2310/6650.2005.X0004.56  0.426
2006 Reckamp KL, Czernin J, Weber WA, Dubinett SM, Figlin RA. Targeted COX-2 and EGFR TK inhibition in advanced non-small cell lung cancer Journal of Clinical Oncology. 24: 7179-7179. DOI: 10.1200/Jco.2006.24.18_Suppl.7179  0.451
2006 Azarian V, Gangloff A, Seimbille Y, Delaloye S, Czernin J, Phelps ME, Silverman DHS. Synthesis and liposome encapsulation of a novel 18F-conjugate of ω-conotoxin GVIA for the potential imaging of N-type Ca2+ channels in the brain by positron emission tomography Journal of Labelled Compounds and Radiopharmaceuticals. 49: 269-283. DOI: 10.1002/Jlcr.1029  0.368
2005 Czernin J, Auerbach MA. Clinical PET/CT imaging: Promises and misconceptions Nuklearmedizin. 44. PMID 16395974 DOI: 10.1055/S-0038-1625210  0.443
2005 Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J, Phelps ME, Silverman DH. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 1866-71. PMID 16269601  0.775
2005 Halpern BS, Schiepers C, Weber WA, Crawford TL, Fueger BJ, Phelps ME, Czernin J. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest. 128: 2289-97. PMID 16236886 DOI: 10.1016/S0012-3692(15)52634-2  0.408
2005 Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratib O, Phelps ME, Czernin J. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 7: 369-76. PMID 16220355 DOI: 10.1007/S11307-005-0013-4  0.45
2005 Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DH. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 1455-9. PMID 16157527  0.305
2005 Brunken RC, Perloff JK, Czernin J, Campisi R, Purcell S, Miner PD, Child JS, Schelbert HR. Myocardial perfusion reserve in adults with cyanotic congenital heart disease. American Journal of Physiology. Heart and Circulatory Physiology. 289: H1798-806. PMID 16006539 DOI: 10.1152/Ajpheart.01309.2004  0.466
2005 Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 945-52. PMID 15937304  0.371
2005 Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 587-95. PMID 15809480  0.352
2005 Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J, Phelps ME, Silverman DH, Sawyers CL, Czernin J. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 114-20. PMID 15632041  0.629
2005 Seimbille Y, Phelps ME, Czernin J, Silverman DHS. Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: Synthesis of18F-Iressa and related molecular probes Journal of Labelled Compounds and Radiopharmaceuticals. 48: 829-843. DOI: 10.1002/Jlcr.998  0.416
2005 Seimbille Y, Czernin J, Phelps ME, Silverman DHS. Synthesis of an18F-fluorobenzoate idarubicin derivative as new potential PET radiotracer to predict chemotherapy resistance Journal of Labelled Compounds and Radiopharmaceuticals. 48: 819-827. DOI: 10.1002/Jlcr.990  0.406
2005 Lacan G, Kesner AL, Gangloff A, Zheng L, Czernin J, Melega WP, Silverman DHS. Synthesis of 2-[(2-chloro-2′-[18F]fluoroethyl)amino]-2H-1, 3,2-oxazaphosphorinane-2-oxide (18F-fluorocyclophosphamide), a potential tracer for breast tumor prognostic imaging with PET Journal of Labelled Compounds and Radiopharmaceuticals. 48: 635-643. DOI: 10.1002/Jlcr.954  0.78
2004 Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH, Ratib O, Phelps ME, Czernin J. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 6: 411-6. PMID 15564152 DOI: 10.1016/J.Mibio.2004.08.004  0.437
2004 Obrzut SL, Halpern BS, Monchamp T, Grabski K, Watts WJ, Czernin J. The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography in monitoring the immunosuppressive therapy response of inflammatory myofibroblastic tumor. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 6: 126-30. PMID 15193246 DOI: 10.1016/J.Mibio.2004.03.003  0.454
2004 Filmont JE, Yap CS, Ko F, Vranjesevic D, Quon A, Margolis DJ, Safaei A, Emmanouilides C, Silverman DH, Phelps ME, Czernin J. Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 6: 47-54. PMID 15018828 DOI: 10.1016/S1536-1632(03)00107-0  0.66
2004 Halpern BS, Dahlbom M, Waldherr C, Yap CS, Schiepers C, Silverman DH, Ratib O, Czernin J. Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 45: 290-3. PMID 14960650  0.315
2003 Silverman DH, Truong CT, Kim SK, Chang CY, Chen W, Kowell AP, Cummings JL, Czernin J, Small GW, Phelps ME. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Molecular Genetics and Metabolism. 80: 350-5. PMID 14680983 DOI: 10.1016/S1096-7192(03)00139-2  0.422
2003 Pio BS, Byrne FR, Aranda R, Boulay G, Spicher K, Song MH, Birnbaumer L, Phelps ME, Czernin J, Silverman DH. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 5: 271-7. PMID 14499142 DOI: 10.1016/S1536-1632(03)00103-3  0.449
2003 Filmont JE, Vranjesevic D, Quon A, Margolis DJ, Ko F, Safaei A, Emmanouilides C, Silverman DH, Rao J, Valk PE, Phelps ME, Czernin J. Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 5: 232-9. PMID 14499138 DOI: 10.1016/S1536-1632(03)00086-6  0.656
2003 Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME, Emmanouilides C. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest. 124: 608-13. PMID 12907550 DOI: 10.1378/Chest.124.2.608  0.414
2003 Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma European Journal of Nuclear Medicine and Molecular Imaging. 30. PMID 12719922 DOI: 10.1007/S00259-003-1165-6  0.438
2002 Wong C, Silverman DH, Seltzer M, Schiepers C, Ariannejad M, Gambhir SS, Phelps ME, Rao J, Valk P, Czernin J. The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 4: 185-90. PMID 14537142 DOI: 10.1016/S1536-1632(01)00003-8  0.44
2002 Silverman DH, Cummings JL, Small GW, Gambhir SS, Chen W, Czernin J, Phelps ME. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 4: 283-93. PMID 14537119 DOI: 10.1016/S1536-1632(02)00016-1  0.403
2002 Czernin J. Clinical applications of FDG-PET in oncology Acta Medica Austriaca. 29: 162-170. PMID 12506767 DOI: 10.1046/J.1563-2571.2002.02042.X  0.461
2002 Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? European Journal of Nuclear Medicine and Molecular Imaging. 29: 1166-73. PMID 12192561 DOI: 10.1007/S00259-002-0853-Y  0.445
2002 Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, Gambhir SS, Rao J, Valk PE, Czernin J. The impact of PET on the management of lung cancer: the referring physician's perspective. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 43: 752-6. PMID 12050318  0.33
2002 Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, Valk PE, Czernin J. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 43: 325-9. PMID 11884491  0.325
2002 Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, Czernin J. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clinical Nephrology. 57: 56-62. PMID 11837802  0.599
2002 Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annual Review of Medicine. 53: 89-112. PMID 11818465 DOI: 10.1146/Annurev.Med.53.082901.104028  0.452
2002 Czernin J. FDG-PET in breast cancer: A different view of its clinical usefulness Molecular Imaging and Biology. 4: 35-45. DOI: 10.1016/S1095-0397(01)00069-3  0.38
2001 Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. Jama. 286: 2120-7. PMID 11694153 DOI: 10.1001/Jama.286.17.2120  0.385
2001 Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, Valk PE, Czernin J. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 42: 1334-7. PMID 11535721  0.315
2001 Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 42: 1S-93S. PMID 11483694  0.331
2001 Schöder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps ME, Valk PE, Sayre J, Czernin J. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 42: 1139-43. PMID 11483671  0.331
2001 Meta J, Seltzer M, Schiepers C, Silverman DH, Ariannejad M, Gambhir SS, Phelps ME, Valk P, Czernin J. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 42: 586-90. PMID 11337546  0.351
2001 Park KC, Schwimmer J, Shepherd JE, Phelps ME, Czernin JR, Schiepers C, Gambhir SS. Decision analysis for the cost-effective management of recurrent colorectal cancer. Annals of Surgery. 233: 310-9. PMID 11224617 DOI: 10.1097/00000658-200103000-00003  0.301
2000 Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, Phelps ME, Czernin J, Gambhir SS. A review of the literature for whole-body FDG PET in the management of patients with melanoma. The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [and] the International Association of Radiopharmacology (Iar). 44: 153-67. PMID 10967625  0.332
2000 Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 41: 1177-89. PMID 10914907  0.324
2000 Schöder H, Silverman DH, Campisi R, Sayre JW, Phelps ME, Schelbert HR, Czernin J. Regulation of myocardial blood flow response to mental stress in healthy individuals. American Journal of Physiology. Heart and Circulatory Physiology. 278: H360-6. PMID 10666065 DOI: 10.1152/Ajpheart.2000.278.2.H360  0.49
1999 Auerbach MA, Schöder H, Hoh C, Gambhir SS, Yaghoubi S, Sayre JW, Silverman D, Phelps ME, Schelbert HR, Czernin J. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation. 99: 2921-6. PMID 10359737 DOI: 10.1161/01.Cir.99.22.2921  0.54
1999 Schöder H, Campisi R, Ohtake T, Hoh CK, Moon DH, Czernin J, Schelbert HR. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction Journal of the American College of Cardiology. 33: 1328-1337. PMID 10193735 DOI: 10.1016/S0735-1097(99)00010-8  0.584
1998 Baumgartner H, Porenta G, Lau YK, Wutte M, Klaar U, Mehrabi M, Siegel RJ, Czernin J, Laufer G, Sochor H, Schelbert H, Fishbein MC, Maurer G. Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT: correlation with histopathology in explanted hearts. Journal of the American College of Cardiology. 32: 1701-8. PMID 9822099 DOI: 10.1016/S0735-1097(98)00436-7  0.578
1998 Campisi R, Czernin J, Schöder H, Sayre JW, Marengo FD, Phelps ME, Schelbert HR. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation. 98: 119-25. PMID 9679717 DOI: 10.1161/01.Cir.98.2.119  0.464
1998 Silverman DH, Hoh CK, Seltzer MA, Schiepers C, Cuan GS, Gambhir SS, Zheng L, Czernin J, Phelps ME. Evaluating tumor biology and oncological disease with positron-emission tomography. Seminars in Radiation Oncology. 8: 183-96. PMID 9634495 DOI: 10.1016/S1053-4296(98)80044-1  0.463
1998 Hoh CK, Seltzer MA, Ting Au Yong, Czernin J, Silverman DHS, Gambhir SS, Phelps ME, Karlan BY. Positron emission tomography in gynecologic malignancies Journal of Gynecologic Techniques. 4: 19-24.  0.355
1997 Campisi R, Czernin J, Karpman HL, Schelbert HR. Coronary vasodilatory capacity and flow reserve in normal myocardium supplied by bypass grafts late after surgery American Journal of Cardiology. 80: 27-31. PMID 9205015 DOI: 10.1016/S0002-9149(97)00278-6  0.495
1997 Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, Maddahi J, Phelps ME. PET in oncology: will it replace the other modalities? Seminars in Nuclear Medicine. 27: 94-106. PMID 9144854 DOI: 10.1016/S0001-2998(97)80042-6  0.47
1997 Kofoed KF, Czernin J, Johnson J, Kobashigawa J, Phelps ME, Laks H, Schelbert HR. Effects of cardiac allograft vasculopathy on myocardial blood flow, vasodilatory capacity, and coronary vasomotion. Circulation. 95: 600-6. PMID 9024146 DOI: 10.1161/01.Cir.95.3.600  0.475
1996 Maddahi J, Czernin J. Absolute quantitation of myocardial blood flow: The technical and clinical prospects for single-photon emission computed tomography Journal of Nuclear Cardiology. 3. PMID 8989688 DOI: 10.1016/S1071-3581(96)90209-3  0.308
1996 Sun KT, Czernin J, Krivokapich J, Lau YK, Böttcher M, Maurer G, Phelps ME, Schelbert HR. Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium. Circulation. 94: 3146-54. PMID 8989122 DOI: 10.1161/01.Cir.94.12.3146  0.556
1996 Krivokapich J, Czernin J, Schelbert HR. Dobutamine positron emission tomography: Absolute quantitation of rest and dobutamine myocardial blood flow and correlation with cardiac work and percent diameter stenosis in patients with and without coronary artery disease Journal of the American College of Cardiology. 28: 565-572. PMID 8772740 DOI: 10.1016/0735-1097(96)00205-7  0.513
1996 Nitzsche EU, Choi Y, Czernin J, Hoh CK, Huang SC, Schelbert HR. Noninvasive Quantification of Myocardial Blood Flow in Humans: A Direct Comparison of the [13N] Ammonia and the [15O]Water Techniques Circulation. 93: 2000-2006. PMID 8640974 DOI: 10.1161/01.Cir.93.11.2000  0.494
1995 Di Carli M, Czernin J, Hoh CK, Gerbaudo VH, Brunken RC, Huang SC, Phelps ME, Schelbert HR. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation. 91: 1944-51. PMID 7895351 DOI: 10.1161/01.Cir.91.7.1944  0.508
1995 Sinha S, Sinha U, Czernin J, Porenta G, Schelbert HR. Noninvasive assessment of myocardial perfusion and metabolism: Feasibility of registering gated MR and PET images American Journal of Roentgenology. 164: 301-307. PMID 7839959 DOI: 10.2214/Ajr.164.2.7839959  0.556
1995 Czernin J, Sun K, Brunken R, Bottcher M, Phelps M, Schelbert H. Effect of acute and long-term smoking on myocardial blood flow and flow reserve Circulation. 91: 2891-2897. PMID 7796497 DOI: 10.1161/01.Cir.91.12.2891  0.478
1995 Czernin J, Barnard RJ, Sun KT, Krivokapich J, Nitzsche E, Dorsey D, Phelps ME, Schelbert HR. Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation. 92: 197-204. PMID 7600651 DOI: 10.1161/01.Cir.92.2.197  0.481
1995 Bottcher M, Czernin J, Sun K, Porenta G, Dicarli M, Buxton D, Schelbert H. Inter and intra observer variability of myocardial blood flow measurements using positron emission tomography Journal of Nuclear Cardiology. 2. DOI: 10.1016/S1071-3581(05)80236-3  0.543
1995 BOTTCHER M, CZERNIN J, SCHELBERT H. Beneficial effect of β-blockade on hyperemic myocardial blood flow and vasodilatory capacity in humans Journal of Nuclear Cardiology. 2: S6-S6. DOI: 10.1016/S1071-3581(05)80111-4  0.481
1994 Carli MFD, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, Czernin J, Rokhsar S, Stevenson LW, Laks H, Hawkins R, Schelbert HR, Phelps ME, Maddahi J. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction American Journal of Cardiology. 73: 527-533. PMID 8147295 DOI: 10.1016/0002-9149(94)90327-1  0.335
1994 Müller P, Czernin J, Choi Y, Aguilar F, Nitzsche EU, Buxton DB, Sun K, Phelps ME, Huang SC, Schelbert HR. Effect of exercise supplementation during adenosine infusion on hyperemic blood flow and flow reserve. American Heart Journal. 128: 52-60. PMID 8017284 DOI: 10.1016/0002-8703(94)90009-4  0.493
1993 Czernin J, Porenta G, Brunken R, Krivokapich J, Chen K, Bennett R, Hage A, Fung C, Tillisch J, Phelps ME. Regional blood flow, oxidative metabolism, and glucose utilization in patients with recent myocardial infarction. Circulation. 88: 884-95. PMID 8353915 DOI: 10.1161/01.Cir.88.3.884  0.389
1993 Czernin J, Müller P, Chan S, Brunken RC, Porenta G, Krivokapich J, Chen K, Chan A, Phelps ME, Schelbert HR. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation. 88: 62-9. PMID 8319357 DOI: 10.1161/01.Cir.88.1.62  0.478
1992 Chan SY, Brunken RC, Czernin J, Porenta G, Kuhle W, Krivokapich J, Phelps ME, Schelbert HR. Comparison of maximal myocardial blood flow during adenosine infusion with that of intravenous dipyridamole in normal men. Journal of the American College of Cardiology. 20: 979-85. PMID 1527310 DOI: 10.1016/0735-1097(92)90201-W  0.494
1992 Porenta G, Czernin J, Schelbert H. Positron emission tomography: Principles and applications in cardiology Wiener Medizinische Wochenschrift. 142: 358-367. PMID 1481541  0.326
1992 Khanna S, DeGroof M, Porenta G, Czernin J, Carli MD, Brunken R, Kim A, Phelps M, Hawkins R, Schelbert H, Maddahi J. ARE GENDER OR PHARMACOLOGIC STRESS-SPECIFIC REFERENCE NORMAL DATABASES NECESSARY FOR QUANTITATIVE ANALYSIS OF STRESS N-13 AMMONIA PET IMAGES? Clinical Nuclear Medicine. 17: 765. DOI: 10.1097/00003072-199209000-00048  0.329
1991 Czernin J, Chan S, Brunken R, Porenta G, Phelps M, Schelbert H. Accuracy of early pet blood flow and metabolic measurements for predicting late improvement in the clinical infarct zone Journal of the American College of Cardiology. 17: A347. DOI: 10.1016/0735-1097(91)92352-M  0.565
1991 Czernin J, Porenta G, Brunken R, Bennet R, Tillisch J, Phelps M, Schelbert H. Metabolic and functional fate of viable myocardium by pet early after acute infarction Journal of the American College of Cardiology. 17: A120. DOI: 10.1016/0735-1097(91)91447-M  0.572
Show low-probability matches.